Books in Pharmaceutical sciences

11-20 of 466 results in All results

Advanced Drug Delivery Systems for Colonic Disorders

1st Edition
Harish Dureja, Raimar Loebenberg + 3 more
Harish Dureja, Raimar Loebenberg, Sachin Kumar Singh + 2 more
November 4, 2023

Paperback
9 7 8 - 0 - 4 4 3 - 1 4 0 4 4 - 0
eBook
9 7 8 - 0 - 4 4 3 - 1 4 0 4 5 - 7

Advanced Drug Delivery Systems for Colonic Disorders presents state-of-the-art methods for targeted drug delivery to the colon. These methods can prolong drug half-lives, improve bioavailability, optimize pharmacokinetics, and reduce medication dosing frequency. Chapters allow readers to not only become familiar with advancements, but also understand concepts by providing illustrations, figures, and informative tables. Contents cover an overview of colonic diseases, the cellular and molecular mechanisms involved, current and traditional therapeutic approaches, biomaterials, oral drug delivery methods, targeted drug delivery, nutraceuticals and herbal medicine approaches, prebiotics, probiotics and symbiotics, nanomedicine approaches, and the status of clinical trials.This book is the perfect resources for researchers in pharma, biomaterials, and nutrition to help familiarize them with new and upcoming therapeutic methods. Research physicians in GI can also benefit from reading this book for its clinical applications.

Image - Advanced Drug Delivery Systems for Colonic Disorders

Advanced Drug Delivery Systems in the Management of Cancer

1st Edition
Kamal Dua, Meenu Mehta + 4 more
Kamal Dua, Meenu Mehta, Terezinha de Jesus Andreoli Pinto + 3 more
June 23, 2021

Paperback
9 7 8 - 0 - 3 2 3 - 8 5 5 0 3 - 7
eBook
9 7 8 - 0 - 3 2 3 - 9 0 0 7 9 - 9

Advanced Drug Delivery Systems in the Management of Cancer discusses recent developments in nanomedicine and nano-based drug delivery systems used in the treatment of cancers affecting the blood, lungs, brain, and kidneys. The research presented in this book includes international collaborations in the area of novel drug delivery for the treatment of cancer. Cancer therapy remains one of the greatest challenges in modern medicine, as successful treatment requires the elimination of malignant cells that are closely related to normal cells within the body. Advanced drug delivery systems are carriers for a wide range of pharmacotherapies used in many applications, including cancer treatment. The use of such carrier systems in cancer treatment is growing rapidly as they help overcome the limitations associated with conventional drug delivery systems. Some of the conventional limitations that these advanced drug delivery systems help overcome include nonspecific targeting, systemic toxicity, poor oral bioavailability, reduced efficacy, and low therapeutic index. This book begins with a brief introduction to cancer biology. This is followed by an overview of the current landscape in pharmacotherapy for the cancer management. The need for advanced drug delivery systems in oncology and cancer treatment is established, and the systems that can be used for several specific cancers are discussed. Several chapters of the book are devoted to discussing the latest technologies and advances in nanotechnology. These include practical solutions on how to design a more effective nanocarrier for the drugs used in cancer therapeutics. Each chapter is written with the goal of informing readers about the latest advancements in drug delivery system technologies while reinforcing understanding through various detailed tables, figures, and illustrations. Advanced Drug Delivery Systems in the Management of Cancer is a valuable resource for anyone working in the fields of cancer biology and drug delivery, whether in academia, research, or industry. The book will be especially useful for researchers in drug formulation and drug delivery as well as for biological and translational researchers working in the field of cancer.

Image - Advanced Drug Delivery Systems in the Management of Cancer

Advanced Issue Resolution in Safety Pharmacology

1st Edition
Mary Jeanne Kallman + 1 more
Mary Jeanne Kallman and Michael Pugsley
September 5, 2018

Hardback
9 7 8 - 0 - 1 2 - 8 1 2 2 0 6 - 8
eBook
9 7 8 - 0 - 1 2 - 8 1 2 3 3 4 - 8

Advanced Issue Resolution in Safety Pharmacology not only discusses unique issues that may emerge during the development of new medicines, but also provides detailed insights on how to resolve them. The book employs a valuable strategy that integrates preclinical findings with the clinical resolution of those findings. In addition, it introduces key interdisciplinary topics in an accessible and systematic format. Edited and written by leaders in the field of safety pharmacology, this book considerably advances the discussion on issue resolution topics, thus raising them to the next level of importance by providing scientists with an indispensable resource on solving safety issues.

Image - Advanced Issue Resolution in Safety Pharmacology

Advanced Nanoformulations

1st Edition
Md Saquib Hasnain, Amit Kumar Nayak + 1 more
Md Saquib Hasnain, Amit Kumar Nayak and Tejraj M. Aminabhavi
March 22, 2023

Paperback
9 7 8 - 0 - 3 2 3 - 8 5 7 8 5 - 7
eBook
9 7 8 - 0 - 3 2 3 - 8 8 5 7 9 - 9

Advanced Nanoformulations: Theranostic Nanosystems, Volume Three examines the applications of nanotherapeutic systems and nanodiagnostics in relation to polymeric nanosystems. In the last decade, numerous biopolymers have been utilized to prepare polymeric nanosystems for therapeutic applications. These biopolymers include polylactic acid, polylactide-co-glycolide, polycaprolactone, acrylic polymers, cellulose and cellulose derivatives, alginates, chitosan, gellan gum, gelatin, albumin, chontroitin sulfate, hyaluronic acid, guar gum, gum Arabic, gum tragacanth, xanthan gum, and starches. Besides these biopolymers, grafted polymers are also being used as advanced polymeric materials to prepare many theranostic nanocarriers and nanoformulations. This book explores the array of polymeric nanosystems to understand therapeutic potentials. It will be useful to pharmaceutical scientists, including industrial pharmacists and analytical scientists, health care professionals, and regulatory scientists actively involved in the pharmaceutical product and process development of tailor-made polysaccharides in drug delivery applications.

Advanced and Modern Approaches for Drug Delivery

1st Edition
Amit Kumar Nayak, Md Saquib Hasnain + 2 more
Amit Kumar Nayak, Md Saquib Hasnain, Bibek Laha + 1 more
July 29, 2023

Paperback
9 7 8 - 0 - 3 2 3 - 9 1 6 6 8 - 4
eBook
9 7 8 - 0 - 3 2 3 - 9 7 2 1 9 - 2

Advanced and Modern Approaches for Drug Delivery explores novel approaches currently used for drug delivery, including the must up-to-date techniques and technology. The approaches discussed allow pharmaceutical scientists to design effective drug delivery systems or devices for the management and treatment of numerous diseases and conditions. Detailed information on a wide variety of subjects, including dendrimers, lipid nanostructures, solid lipid nanoparticles, stimuli-responsive smart systems, self-assembled protein-drug nanoparticles, nanoconjugate formulations, nanofibers, iontophoretic systems, microneedle systems, ultra-sound triggered systems, targeted carrier-based intracellular delivery systems, resealed erythrocyte-based systems, 3 D-printing tool, site-specific monoclonal antibodies, and bio-inspired systems are all comprehensively discussed. With contributions from those in academia and industry, this book is an excellent reference for all those needing to understand drug delivery systems.

Image - Advanced and Modern Approaches for Drug Delivery

Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents

1st Edition
Manju Rawat Singh, Deependra Singh + 2 more
Manju Rawat Singh, Deependra Singh, Jagat Kanwar + 1 more
April 7, 2020

Paperback
9 7 8 - 0 - 1 2 - 8 1 9 6 6 6 - 3
eBook
9 7 8 - 0 - 1 2 - 8 1 9 9 1 8 - 3

Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents provides sound data on the utility of biological and plant-based drugs and describes challenges faced in all aspects offering indispensable strategies to use in the development of bioactive medicines. Bioactive based medications are commonly used throughout the world and have been recognized by physicians and patients for their therapeutic efficacy. Bioactive formulations, including their subordinates and analogs, address 50% of all medicines in clinical practice. Novel bioactive medicine transporters can cure many disorders by both spatial and transitory approaches and have various justifications in medicinal potential. This book presents information on the utility of natural, plant, animal and bioengineered bioactive materials. It is a fundamental source of information and data for pharmacognosists, pharmaceutical analysts, drug transport scientists and pharmacologists working in bioactive medications.

Image - Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents

Advances and Challenges in Pharmaceutical Technology

1st Edition
Amit Kumar Nayak, Kunal Pal + 3 more
Amit Kumar Nayak, Kunal Pal, Indranil Banerjee + 2 more
February 9, 2021

Paperback
9 7 8 - 0 - 1 2 - 8 2 0 0 4 3 - 8
eBook
9 7 8 - 0 - 1 2 - 8 2 0 3 0 0 - 2

Advances and Challenges in Pharmaceutical Technology: Materials, Process Development and Drug Delivery Strategies examines recent advancements in pharmaceutical technology. The book discusses common formulation strategies, including the use of tools for statistical formulation optimization, Quality by design (QbD), process analytical technology, and the uses of various pharmaceutical biomaterials, including natural polymers, synthetic polymers, modified natural polymers, bioceramics, and other bioinorganics. In addition, the book covers rapid advancements in the field by providing a thorough understanding of pharmaceutical processes, formulation developments, explorations, and exploitation of various pharmaceutical biomaterials to formulate pharmaceutical dosage forms.

Image - Advances and Challenges in Pharmaceutical Technology

Advances in Antiviral Drug Design

1st Edition
E. De Clercq
E. De Clercq
December 17, 2003

Hardback
9 7 8 - 0 - 4 4 4 - 5 0 6 0 2 - 3
eBook
9 7 8 - 0 - 0 8 - 0 5 2 2 2 6 - 5

The fourth volume of Advances in Antiviral Drug Design is keeping up with the recent progress made in the broad field of antiviral drug research and encompasses six specific directions that have opened new avenues for the treatment of HIV and other virus infections.First, as the introductory chapter, the different new anti-HIV agents that are now in preclinical or clinical development are reviewed by E. De Clercq. This includes new NRTIs, NNRTIs and PIs, but also HIV entry/fusion inhibitors as well as integrase inhibitors, and some of these agents, such as the NRTI emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed for clinical use.Second, high expectations are vested in the potential therapeutic usefulness of inhibitors of HIV integration, a point of no return in the life cycle of HIV, and this approach is highlighted by D.J. Hazuda and S.D. Young.Third, as all currently available PIs can be described as "peptidomimetic", and, therefore, expected to demonstrate overlapping virus-drug resistance and side effect profiles, it would be interesting to see how a non-peptidic protease inhibitor such as tipranavir behaves, and this is covered by D. Mayers, K. Curry, V. Kohlbrenner and S. McCallister.Fourth, neuraminidase inhibitors such as zanamivir (that has to be inhaled) and oseltamivir (that can be administered via the oral route) have gained a definitive status as antiviral drugs useful for both therapy and prophylaxis of influenza A and B virus infections; as they target a specific influenza viral enzyme, neuraminidase (or sialidase), they may be expected to block newly emerging influenza viruses as well, and the design of neuraminidase inhibitors has received due attention of H. Jin and C.U. Kim.Fifth, while the major current efforts in antiviral drug development have shifted from herpesviruses towards HIV and hepatitis viruses [hepatitis B virus (HBV), hepatitis C virus (HCV)], it is interesting to note that by switching from the classical five-membered sugar or acyclic nucleoside strategy, J. Wang, M. Froeyen and P. Herdewijn have gone "upstream" in designing six-membered carbocyclic nucleosides as potential anti-herpesvirus agents.Sixth, following up on the nucleotide prodrug strategy introduced above under ix, to deliver the biologically active nucleotides inside the cells, C. Meier has elaborated on a particular class of such pronucleotides, namely that of the cyclosaligenyl pronucleotides, an approach that should have far reaching implications for compounds effective against HIV, HBV and other viruses.The six topics covered in this fourth volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the design and development of new therapeutic agents for virus infections. They pertain to the combat against three of the most important viral pathogens of current times: HIV, HBV, influenza virus and herpesviruses.

Advances in Antiviral Drug Design

1st Edition
E. De Clercq
E. De Clercq
July 30, 2007

Hardback
9 7 8 - 0 - 4 4 4 - 5 2 1 7 3 - 6
eBook
9 7 8 - 0 - 0 8 - 0 5 4 8 2 4 - 1

Regularly reviewing the "state-of-the-art" developments in the antiviral drug research field, this latest volume spans the conceptual design and chemical synthesis of new antiviral compounds. It discusses their structure-activity relationship, mechanism and targets of action, pharmacological behavior, antiviral activity spectrum, and therapeutic potential for clinical use.

Advances in Antiviral Drug Design

1st Edition
E. De Clercq
E. De Clercq
November 22, 1999

Hardback
9 7 8 - 0 - 7 6 2 3 - 0 2 0 1 - 7
eBook
9 7 8 - 0 - 0 8 - 0 5 2 6 0 4 - 1

Volume 3 of Advances in Antiviral Drug Design is keeping up with the recent progress made in the field of antiviral drug research and highlights five specific directions that have opened new avenues for the treatment of virus infections. First, the use of lamivudine (3TC) for the treatment of HIV infections, and its more recent introduction for the treatment of hepatitis B virus (HBV) infections, has heralded the transition of D- to L-nucleosides in the antiviral nucleoside drug design, and it is likely that the future will provide more nucleosides of the L-configuration, such as (-)FFC (emtricitabine) and L-FMAU, as will be described by J.-C.G. Graciet and R.F. Shinazi. Second, the acyclic purine nucleoside phosphonates, i.e. PMEA (adefovir and PMPA (tenofovir), offer great potential as both anti-HIV and anti-HBV agents, and both compounds have been the subject of advanced clinical trials in their oral produrg form (adefovir dipivoxil and tenofovir disoproxyl), as mentioned by M.N. Arimilli, J.P. Dougherty, K.C. Cundy, and N. Bischofberger.Third, with the advent of nevirapine, delavirdine, and efavirenz, the NNRTIs have definitely come of age. Emivirine (MKC-442), a derivative of the original HEPT analog that was described in 1989 has now proceeded through pivotal clinical studies, and how this class of compounds evolved is presented in the account of H. Tanaka and his colleagues. Fourth, at the end of 1999, anticipating on the next winter influenza offensive, we should have at end two compounds that specifically inhibit influenza A and B virus infections: zanamivir (by the intranasal route) and oseltamivir (by the oral route). Both compounds have proved effective in the prophylaxis and treatment of influenza A and B virus infections and act through the same mechanism; that is by blocking the viral neuraminidase (or sialidase), a key enzyme that allows the virus to spread from one cell to another (within the respiratory mucosal tract). The design of these sialidase inhibitors will be presented by M. von Itzstein and J.C. Dyason.Fifth, the discovery (in 1996) of the chemokine receptors CXCR4 and CCR5 as essential coreceptors (in addition to the CD4 receptor) for HIV entry into the cells, has boosted an enormous interest in potential antagonists of these receptors. The bicyclams represent the first low-molecular-weight compounds targeted at CXCR4, the coreceptor used by the more pathogenic, T-lymphotropic, HIV strains, to enter the cells. They will be addressed by G.J. Bridger and R.T. Skerlj.The five topics covered in this third volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the chemotherapy of virus infections. They pertain to the combat against three of the most important virus infections of current times: HIV, HBV, and influenza virus.